Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant pembrolizumab for resectable high-risk cutaneous squamous cell carcinoma
ACTRN12621000901808Phase 2Recruiting
- Sponsor
- Metro South Health
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC) and head and neck cancer (HNC), sponsored by Metro South Health. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on ACTRN12621000901808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000901808.